572 related articles for article (PubMed ID: 27318831)
21. Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor): Implications for the Efficacy of Evolocumab.
Thedrez A; Blom DJ; Ramin-Mangata S; Blanchard V; Croyal M; Chemello K; Nativel B; Pichelin M; Cariou B; Bourane S; Tang L; Farnier M; Raal FJ; Lambert G
Arterioscler Thromb Vasc Biol; 2018 Mar; 38(3):592-598. PubMed ID: 29284604
[TBL] [Abstract][Full Text] [Related]
22. Long-term Low-Density Lipoprotein Cholesterol-Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia: Results Up to 4 Years From the Open-Label OSLER-1 Extension Study.
Koren MJ; Sabatine MS; Giugliano RP; Langslet G; Wiviott SD; Kassahun H; Ruzza A; Ma Y; Somaratne R; Raal FJ
JAMA Cardiol; 2017 Jun; 2(6):598-607. PubMed ID: 28291870
[TBL] [Abstract][Full Text] [Related]
23. Familial hypercholesterolemia and estimation of US patients eligible for low-density lipoprotein apheresis after maximally tolerated lipid-lowering therapy.
Vishwanath R; Hemphill LC
J Clin Lipidol; 2014; 8(1):18-28. PubMed ID: 24528684
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia.
Rosenson RS; Jacobson TA; Preiss D; Djedjos CS; Dent R; Bridges I; Miller M
Cardiovasc Drugs Ther; 2016 Jun; 30(3):305-13. PubMed ID: 27240673
[TBL] [Abstract][Full Text] [Related]
25. Low-density lipoprotein apheresis: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2007; 7(5):1-101. PubMed ID: 23074505
[TBL] [Abstract][Full Text] [Related]
26. Switching from lipoprotein apheresis to evolocumab in FH siblings on hemodialysis: case reports and discussion.
Ishii T; Ogura M; Nakamori H; Hori M; Harada-Shiba M; Tamura K; Oyama K
CEN Case Rep; 2021 Nov; 10(4):592-597. PubMed ID: 34100221
[TBL] [Abstract][Full Text] [Related]
27. Disease control via intensified lipoprotein apheresis in three siblings with familial hypercholesterolemia.
Taylan C; Schlune A; Meissner T; Ažukaitis K; Udink Ten Cate FE; Weber LT
J Clin Lipidol; 2016; 10(6):1303-1310. PubMed ID: 27919346
[TBL] [Abstract][Full Text] [Related]
28. Impact of Age on the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia.
Ginsberg HN; Tuomilehto J; Hovingh GK; Cariou B; Santos RD; Brown AS; Sanganalmath SK; Koren A; Thompson D; Raal FJ
Cardiovasc Drugs Ther; 2019 Feb; 33(1):69-76. PubMed ID: 30734207
[TBL] [Abstract][Full Text] [Related]
29. Long-Term Evolocumab in Patients With Familial Hypercholesterolemia.
Santos RD; Stein EA; Hovingh GK; Blom DJ; Soran H; Watts GF; López JAG; Bray S; Kurtz CE; Hamer AW; Raal FJ
J Am Coll Cardiol; 2020 Feb; 75(6):565-574. PubMed ID: 32057369
[TBL] [Abstract][Full Text] [Related]
30. Effects of Evolocumab on Vitamin E and Steroid Hormone Levels: Results From the 52-Week, Phase 3, Double-Blind, Randomized, Placebo-Controlled DESCARTES Study.
Blom DJ; Djedjos CS; Monsalvo ML; Bridges I; Wasserman SM; Scott R; Roth E
Circ Res; 2015 Sep; 117(8):731-41. PubMed ID: 26228031
[TBL] [Abstract][Full Text] [Related]
31. Apheresis in homozygous familial hypercholesterolemia: the results of a follow-up of all Norwegian patients with homozygous familial hypercholesterolemia.
Græsdal A; Bogsrud MP; Holven KB; Nenseter MS; Narverud I; Langslet G; Brekke M; Retterstøl K; Arnesen KE; Ose L
J Clin Lipidol; 2012; 6(4):331-9. PubMed ID: 22836070
[TBL] [Abstract][Full Text] [Related]
32. Atorvastatin in low-density lipoprotein apheresis-treated patients with homozygous and heterozygous familial hypercholesterolemia.
Goldammer A; Wiltschnig S; Heinz G; Jansen M; Stulnig T; Hörl WH; Derfler K
Metabolism; 2002 Aug; 51(8):976-80. PubMed ID: 12145769
[TBL] [Abstract][Full Text] [Related]
33. Evolocumab (AMG 145) for primary hypercholesterolemia.
Langslet G; Emery M; Wasserman SM
Expert Rev Cardiovasc Ther; 2015 May; 13(5):477-88. PubMed ID: 25824308
[TBL] [Abstract][Full Text] [Related]
34. Multimodal lipid-lowering treatment in pediatric patients with homozygous familial hypercholesterolemia-target attainment requires further increase of intensity.
Klaus G; Taylan C; Büscher R; Schmitt CP; Pape L; Oh J; Driemeyer J; Galiano M; König J; Schürfeld C; Spitthöver R; Schaefer JR; Weber LT; Heibges A; Klingel R
Pediatr Nephrol; 2018 Jul; 33(7):1199-1208. PubMed ID: 29502162
[TBL] [Abstract][Full Text] [Related]
35. Cholesterol efflux mediators in homozygous familial hypercholesterolemia patients on low-density lipoprotein apheresis.
Nenseter MS; Narverud I; Græsdal A; Bogsrud MP; Aukrust P; Retterstøl K; Ose L; Halvorsen B; Holven KB
J Clin Lipidol; 2013; 7(2):109-16. PubMed ID: 23415429
[TBL] [Abstract][Full Text] [Related]
36. Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin/kexin type 9 antibody treatment.
Stiekema LCA; Stroes ESG; Verweij SL; Kassahun H; Chen L; Wasserman SM; Sabatine MS; Mani V; Fayad ZA
Eur Heart J; 2019 Sep; 40(33):2775-2781. PubMed ID: 30561610
[TBL] [Abstract][Full Text] [Related]
37. Long-term effect of low-density lipoprotein apheresis on plasma lipoproteins and coronary heart disease in native vessels and coronary bypass in severe heterozygous familial hypercholesterolemia.
Richter WO; Donner MG; Höfling B; Schwandt P
Metabolism; 1998 Jul; 47(7):863-8. PubMed ID: 9667236
[TBL] [Abstract][Full Text] [Related]
38. Relationship Between Low-Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab.
Shapiro MD; Minnier J; Tavori H; Kassahun H; Flower A; Somaratne R; Fazio S
J Am Heart Assoc; 2019 Feb; 8(4):e010932. PubMed ID: 30755061
[TBL] [Abstract][Full Text] [Related]
39. Effects of evolocumab in individuals with type 2 diabetes with and without atherogenic dyslipidemia: An analysis from BANTING and BERSON.
Lorenzatti AJ; Monsalvo ML; López JAG; Wang H; Rosenson RS
Cardiovasc Diabetol; 2021 Apr; 20(1):94. PubMed ID: 33941192
[TBL] [Abstract][Full Text] [Related]
40. The rebound of lipoproteins after LDL-apheresis. Kinetics and estimation of mean lipoprotein levels.
Kroon AA; van't Hof MA; Demacker PN; Stalenhoef AF
Atherosclerosis; 2000 Oct; 152(2):519-26. PubMed ID: 10998482
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
